Beta Drugs Ltd. – Investor Presentation Summary

Key Operational Highlights

  • Offers a comprehensive oncology portfolio with 180+ Oncology Focused SKUs and 8 products under development.
  • Products available across 85%+ of corporate and government hospitals in India.
  • Exports products across 25+ countries, with a presence in 46+ countries supported by 280+ dossier registrations and a pipeline of 623 future registrations.
  • Operates 3 WHO-GMP certified manufacturing facilities, with one plant having ANVISA, INVIMA & COFEPRIS certifications.
  • Key drivers include a patient-centric R&D approach focusing on Novel Drug Delivery Systems (NDDS), including Liposomes, Nanoparticles and Microparticle technologies, and being a pioneer in Nano-Albumin Bound Paclitaxel, Ready-to-Use Docetaxel and Gemcitabine formulations.

Segment-wise Performance

  • Business Verticals: Diversified revenue mix across four pillars: Domestic Branded Formulations, CMO, API, and Exports. From FY27, IVF revenues from Nivian Lifesciences are consolidated in Domestic Branded Formulations.
  • Q1-FY27 Segmental Performance:
  • Branded Oncology business grew 47% YoY to INR 330 Mn.
  • Contract Manufacturing (CMO) business grew 41% YoY.
  • Export business generated INR 172 Mn revenue.
  • Nivian (IVF) business delivered 45% YoY growth.
  • Explanation of significant changes: Growth was driven by improved performance from existing products, new launches, strong customer traction, and deeper market penetration.

Financial Highlights

Q1-FY27 Consolidated Financial Performance (INR Mn):

  • Revenue: Rs. 1,255
  • EBITDA: Rs. 274
  • PAT: Rs. 165
  • EPS: Rs. 14.78
  • Margins: EBITDA Margin 21.83%, PAT Margin 13.15%
  • YoY/QoQ comparison: Gross margin improved to 56.6% vs. 50.4% in Q1 FY26.
  • Drivers of financial performance: Favourable shift toward higher-margin branded and export businesses.
  • Comparison to market estimates: Not Specified
  • Key Risks: Not Specified

Historical Financial Performance (INR Mn):

| Particular | FY24 | FY25 | FY26 | Q1-FY27 |

| Revenue | 2,957 | 3,624 | 3,848 | 1,255 |

| EBITDA | 600 | 746 | 757 | 274 |

| EBITDA Margin (%) | 20.29% | 20.58% | 19.67% | 21.83% |

| PAT | 364 | 424 | 415 | 165 |

| PAT Margin (%) | 12.31% | 11.70% | 10.78% | 13.15% |

Geographical Revenue Split

  • Domestic vs Export/Regional Revenue: Not Specified with exact values.
  • Regional Breakdown: Export distribution across LATAM, APAC, MENA, Africa, and CIS regions. Region-wise export distribution for FY26 was provided but without specific revenue splits.

Balance Sheet Snapshot

Historical Consolidated Balance Sheet (INR Mn):

| Particular | FY24 | FY25 | FY26 |

| Total Equity & Liabilities | 2,541 | 4,362 | 4,958 |

| Total Non-current Liabilities | 123 | 1,364 | 1,429 |

| Total Current Liabilities | 847 | 1,027 | 1,082 |

| Property, Plant And Equipment | 592 | 804 | 1,154 |

| Inventories | 498 | 598 | 745 |

| Trade Receivables | 792 | 1,026 | 1,191 |

| Cash And Cash Equivalents | 286 | 1,470 | 1,248 |

  • Net Debt/Equity: Not Specified
  • Reserves: Not Specified
  • Current Assets/Liabilities: Not Specified
  • Working Capital/Leverage Metrics: Not Specified
  • Financial Health Insights: Not Specified

Capex & Cash Flow Health

  • Capital Expenditure: Not Specified
  • Free Cash Flow: Not Specified
  • Operating Cash Flow: Not Specified
  • Net Debt Movement: Not Specified
  • Investment Rationale: Focus on capacity expansion, technology upgrades, and EU GMP aligned infrastructure expansion as part of Vision 2030.

Strategic & R&D Initiatives

  • Investments in Innovation: Strong focus on R&D and NDDS technologies. Robust pipeline of NDDS and First-to-Launch products planned across FY27 and FY28.
  • Expected impact on growth: Not Specified quantitatively.
  • Strategic Rationale: Expanding into high-growth markets (exports, IVF, dermatology), reducing operational costs through backward integration (80%+ API used in-house), and improving manufacturing efficiency.

Industry Trends & Business Environment

  • Macro/Industry Trends: The global pharma market is projected to grow from USD 1,583 Bn in CY 2024 to USD 2,100-2,200 Bn in CY 2029P (5.5-6.5% CAGR). Growth drivers include an ageing population, rising adoption of NDDS, increased R&D investments, government support, and rising healthcare expenditure. The oncology segment is the world's fastest-growing pharma segment.
  • Impact on Company: The company is positioned to capitalize on the rising cancer burden, growing adoption of advanced therapies, and expansion into high-growth specialty segments like IVF and dermatology.

Management Commentary & Growth Outlook

  • Strategic Outlook: Vision 2030 strategic transformation is on track, focusing on R&D & Innovation, Margin Expansion & Manufacturing Efficiency, Export Expansion, and Strategic Inorganic Opportunities.
  • FY Guidance: FY27 consolidated revenue growth guidance of 20–25%.
  • Market Share Targets: Long-term target of deriving over 50% of revenue from own branded products.
  • Risks and Opportunities: Not Specified in detail.

Capital Market Data

| Price Data (As on 30th June 2026) | |

| Face Value (INR) | 10.0 |

| Market Price | 2,184.7 |

| 52 Week H/L (INR) | 2,250.0/ 990.1 |

| Market Cap. (INR Mn) | 24,219.3 |

| Equity Shares Outstanding (Mn) | 11.1 |

| 1 Year Avg. trading volume ('000) | 13.0 |

Company Tag